Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10019329 | 0.89 | CYP1A2 (0.43) | SMN1; SMN2HTTNPC1RAB9AL3MBTL1 | |
| SCHEMBL10019309 | 0.84 | CLK4 (0.48) | MAPTSMN1; SMN2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL10019301 | 0.83 | MET (0.51) | MAPTKMT2AHTTLMNA | |
| SCHEMBL10019319 | 0.83 | MAPT (0.46) | MAPTKMT2AMEN1NPC1 | |
| SCHEMBL10019304 | 0.83 | NPC1 (0.44) | NPC1RAB9A | |
| SCHEMBL10019312 | 0.81 | APP (0.42) | MAPTAPPLMNA | |
| SCHEMBL10019308 | 0.81 | ACHE (0.46) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL652881 | 0.79 | TUBB4A (0.63) | MAPTSMN1; SMN2KMT2AMEN1PIK3CA | |
| SCHEMBL18449581 | 0.76 | APP (0.60) | MAPTSMN1; SMN2KMT2AMEN1PIK3CA | |
| SCHEMBL10019337 | 0.75 | CYP1A2 (0.43) | MAPTKMT2AMEN1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119683-B2 | Aryl substituted sulfonamide compounds and their use as anticancer agents | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-21 | — | — | US | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | ARSA, SULT1E1, STS | MAPT 4706/4885SMN1; SMN2 1118/4885SLC29A1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.